KARD · Insider Trading
Kardigan, Inc. Common Stock
Every open-market purchase and sale reported by KARD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Kristin Marie K Reinke | Director | A | +48,368 deriv. | — |
| 2026-07-13 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | A | +20,706 | — |
| 2026-06-24 | Paul L Berns | Director | Buy | +1,250,000 | +$20.00M |
| 2026-06-24 | ARCH Venture Partners XIII, LLC | Director | Buy | +1,250,000 | +$20.00M |
| 2026-06-24 | Kevin Anthony Kelly | 10%+ Owner | Buy | +3,125,000 | +$50.00M |
| 2026-06-22 | Douglas E. Giordano | Director | A | +20,706 | — |
| 2026-06-22 | Kimberly J Popovits | Director | A | +20,706 | — |
| 2026-06-22 | David P Meeker | Director | A | +20,706 | — |
| 2026-06-22 | Brianne Jahn | Chief Financial Officer | A | +79,640 | — |
| 2026-06-22 | John B Moriarty | Chief Legal Officer | A | +47,784 | — |
| 2026-06-22 | Timothy P Walbert | Director | A | +20,706 | — |
| 2026-06-22 | Jay Edelberg | Chief Medical Officer | MIXED | +145,371 | — |
| 2026-06-22 | Paul L Berns | Director | MIXED | +13,812,741 | — |
| 2026-06-22 | Andy Pasternak | Chief Strategy Officer | A | +79,640 | — |
| 2026-06-22 | Anastasios Gianakakos | President & CEO | C | +568,395 | — |
| 2026-06-22 | ARCH Venture Fund XIII, L.P. | 10%+ Owner | C | +13,792,035 | — |
| 2026-06-22 | SCHF CIF 2024, L.P. | 10%+ Owner | C | +13,792,034 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kevin Anthony Kelly | 10%+ Owner | 16,917,034 | $213.83M |
| Paul L Berns | Director | 15,062,741 | $190.39M |
| ARCH Venture Partners XIII, LLC | Director | 15,042,035 | $190.13M |
| ARCH Venture Fund XIII, L.P. | 10%+ Owner | 13,792,035 | $174.33M |
| SCHF CIF 2024, L.P. | 10%+ Owner | 13,792,034 | $174.33M |
| Anastasios Gianakakos | President & CEO | 9,806,633 | $123.96M |
| Jay Edelberg | Chief Medical Officer | 4,643,167 | $58.69M |
| Andy Pasternak | Chief Strategy Officer | 79,640 | $1.01M |
| Brianne Jahn | Chief Financial Officer | 79,640 | $1.01M |
| John B Moriarty | Chief Legal Officer | 47,784 | $603.99K |
| Douglas E. Giordano | Director | 20,706 | $261.72K |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 20,706 | $261.72K |
| Kimberly J Popovits | Director | 20,706 | $261.72K |
| Timothy P Walbert | Director | 20,706 | $261.72K |
| David P Meeker | Director | 20,706 | $261.72K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KARD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.